A pilot study incorporating HER2-directed dendritic cells into neoadjuvant therapy of early stage HER2+ER- breast cancer - ...

Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.

When combined with trastuzumab and chemotherapy, treatment with pembrolizumab was associated with a statistically significant improvement in PFS and OS compared with placebo.

Experts discuss the patient case of Janet, a 58-year-old with her 2 positive metastatic breast cancer, and after 14 months on ...

The FDA has approved Keytruda plus chemotherapy in HER2+ gastric or GEJ adenocarcinoma with PD-L1–positive expression, based on KEYNOTE-811 data.

ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...

Scientists at King’s College London have developed an innovative IgE antibody therapy that activates the immune system to ...

Moffitt Cancer Center researchers have discovered a promising new vaccine strategy for treating a specific type of breast ...

Metastatic breast cancer is complex, requiring holistic care and ongoing treatment, with varying prognosis depending on ...

The FDA granted orphan drug designation to HLX22 for gastric cancer, advancing global phase 3 trials to improve first-line ...

Less than two months ago, 52-year-old Oklahoma State Representative Melissa Provenzano underwent a mastectomy for stage one ...

Researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer. The innovative approach targets human epidermal growth factor receptor 2-positive, estrogen ...